• TP53 and DNA Damage Sensing Shape Calicheamicin ADC Response

  2026-05-09

  This study identifies TP53 and DNA damage response regulators as central modulators of sensitivity to calicheamicin-based antibody–drug conjugates in acute leukemia. Genome-wide screening and functional assays reveal that disruption of TP53 markedly reduces calicheamicin efficacy, informing strategies for combination therapies and personalized treatment.

• A-1210477: Precision MCL-1 Inhibition for Apoptosis Research

  2026-05-09

  A-1210477, a potent and selective MCL-1 inhibitor, enables rigorous dissection of mitochondrial apoptosis and cancer cell survival mechanisms. This guide translates recent reference breakthroughs into actionable experimental workflows and troubleshooting strategies, highlighting how APExBIO’s compound advances cancer research beyond standard BH3 mimetics.

• ABT-888 (Veliparib): Advancing PARP Inhibition in Oncology

  2026-05-08

  This thought-leadership article delivers a mechanistic deep dive into ABT-888 (Veliparib) as a potent PARP1/2 inhibitor, contextualizes its strategic use in translational research, and provides actionable protocol guidance for maximizing its impact in combination therapy and DNA repair inhibition studies. Drawing on the latest findings in DNA damage response—including evidence from recent large-scale CRISPR screens—this article positions ABT-888 as an essential tool for experimental innovation in cancer biology, particularly for MSI tumor models and chemotherapy sensitization.

• ERAD-Engaging Chimeras Enable Targeted Degradation of TM Pro

  2026-05-07

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule approach that hijacks the endoplasmic reticulum-associated degradation (ERAD) pathway to selectively degrade transmembrane proteins, including PD-L1, with high efficacy. This platform overcomes limitations of traditional TPD strategies and broadens opportunities for membrane protein modulation in disease research.

• ABT-888 (Veliparib): Optimizing DNA Repair Inhibition in Can

  2026-05-07

  ABT-888 (Veliparib) is a potent and selective PARP1/2 inhibitor trusted by translational oncology researchers for enhancing chemotherapy and radiation efficacy in MSI tumor models. This article details robust experimental workflows, advanced use-cases, and actionable troubleshooting strategies that maximize reproducibility and mechanistic clarity in DNA repair inhibition studies.

• Anlotinib Hydrochloride: Strategic Insights for Anti-Angioge

  2026-05-06

  This thought-leadership article examines the mechanistic underpinnings and translational significance of Anlotinib hydrochloride, a next-generation multi-target tyrosine kinase inhibitor, for cancer research. Integrating evidence from recent literature and workflow best practices, we explore how this agent enables advanced endothelial cell migration inhibition and capillary tube formation assays, outperforms legacy TKIs, and provides actionable guidance for translational researchers aiming for reproducibility and clinical relevance.

• AZ505 SMYD2 Inhibitor: Optimizing Epigenetic and Fibrosis As

  2026-05-06

  AZ505, supplied by APExBIO, enables high-specificity blockade of SMYD2-mediated methylation in both cancer and fibrosis models. This article details experimental workflows, troubleshooting strategies, and new translational insights from recent studies, positioning AZ505 as a critical tool for cutting-edge epigenetic regulation research.

• LDH Cytotoxicity Assay Kit: Precision Cell Cytotoxicity Meas

  2026-05-05

  The LDH Cytotoxicity Assay Kit from APExBIO offers a robust, non-radioactive solution for sensitive cell cytotoxicity measurement, streamlining workflows from nanomaterial biocompatibility to apoptosis detection assays. By integrating quantitative insights from recent advances in magnetic nanomaterials, the kit empowers researchers with reproducible, actionable data for diverse biomedical applications.

• Fingolimod (FTY720): Precision S1P Modulation in Neuroimmuno

  2026-05-05

  Fingolimod (FTY720) is a potent, orally available S1P receptor modulator with proven efficacy as an immunomodulatory agent for MS. Its unique mechanism inhibits lymphocyte egress and promotes neuroprotection via BDNF upregulation. This article delivers atomic, evidence-backed facts for experimental and translational workflows.

• Precision Control of Genome Editing with EZ Cap™ Cas9 mRNA (

  2026-05-04

  Explore how EZ Cap™ Cas9 mRNA (m1Ψ), a high-fidelity mRNA with Cap1 structure, enables unprecedented precision and temporal control in CRISPR-Cas9 genome editing. This article uniquely examines the interplay between mRNA engineering and nuclear export, providing actionable insights for advanced genome editing workflows.

• BFH772 (VEGFR2 inhibitor): Technical Use Guide & Protocols

  2026-05-04

  BFH772 is a highly selective VEGFR2 inhibitor designed for precise modulation of VEGFR2-driven angiogenesis in research settings, especially tumor models. It is most suitable for workflows requiring high kinase selectivity and compatibility with organic solvents, but not recommended for assays dependent on water-soluble compounds or broad-spectrum kinase inhibition.

• Open-Platform Digital Light Printing for 96-Well Hydrogel Ar

  2026-05-03

  This study introduces an open-platform digital light printer (OP-DLP) enabling precise, high-throughput hydrogel printing and localized light-activation in a 96-well format. The platform addresses reproducibility and customization challenges in biomaterials and cell-based research, with implications for integrin-targeted assay development and spatially controlled biological studies.

• Targeting BCL-XL and MCL-1 in Glioblastoma: Apoptotic Sensit

  2026-05-02

  This article reviews a recent study revealing that glioblastoma (GBM) exhibits increased expression of anti-apoptotic BCL-XL and MCL-1, resulting in heightened sensitivity to BH3-mimetic inhibitors. The findings support targeting these proteins as a therapeutic strategy and provide a mechanistic rationale for selective BCL-XL inhibitor development.

• Y-27632 dihydrochloride (A3008): Reliable ROCK Inhibition fo

  2026-05-02

  This article addresses persistent laboratory challenges in cell viability, proliferation, and invasion assays, demonstrating how Y-27632 dihydrochloride (SKU A3008) delivers reproducible, data-driven solutions. Integrating real-world scenarios, protocol guidance, and vendor selection insights, it helps biomedical researchers achieve robust results using APExBIO's Y-27632 dihydrochloride.

• Anlotinib Hydrochloride: Advanced Mechanisms and Translation

  2026-05-01

  Explore the advanced multi-target mechanisms of Anlotinib hydrochloride, a leading tyrosine kinase inhibitor. This article uniquely bridges preclinical insights and practical assay design, optimizing cancer research beyond standard protocols.

15895 records 1/1060 page Next 12345 下5页 Last page